Ashraf Badros
Ashraf Badros
Professor of Medicine; University of Maryland
Potvrđena adresa e-pošte na
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ...
Nature medicine 21 (8), 914-921, 2015
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
A Badros, D Weikel, A Salama, O Goloubeva, A Schneider, A Rapoport, ...
Journal of clinical oncology 24 (6), 945-952, 2006
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie, R Desikan, P Eddlemon, T Spencer, J Zeldis, N Munshi, ...
Blood, The Journal of the American Society of Hematology 98 (2), 492-494, 2001
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ...
The lancet oncology 21 (2), 207-221, 2020
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
M Zangari, E Anaissie, B Barlogie, A Badros, R Desikan, AV Gopal, ...
Blood, The Journal of the American Society of Hematology 98 (5), 1614-1615, 2001
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ...
Leukemia 27 (4), 780-791, 2013
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
R Desikan, B Barlogie, J Sawyer, D Ayers, G Tricot, A Badros, M Zangari, ...
Blood, The Journal of the American Society of Hematology 95 (12), 4008-4010, 2000
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement
MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ...
Journal of Clinical Oncology 33 (6), 657-664, 2015
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ...
Haematologica 98 (11), 1753, 2013
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport, EA Stadtmauer, N Aqui, A Badros, J Cotte, L Chrisley, ...
Nature medicine 11 (11), 1230-1237, 2005
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
A Badros, B Barlogie, E Siegel, J Roberts, C Langmaid, M Zangari, ...
British journal of haematology 114 (4), 822-829, 2001
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
A Badros, AM Burger, S Philip, R Niesvizky, SS Kolla, O Goloubeva, ...
Clinical Cancer Research 15 (16), 5250-5257, 2009
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
A Badros, B Barlogie, E Siegel, C Morris, R Desikan, M Zangari, A Fassas, ...
British journal of haematology 114 (3), 600-607, 2001
Neurotoxicity of bortezomib therapy in multiple myeloma: a single‐center experience and review of the literature
A Badros, O Goloubeva, JS Dalal, I Can, J Thompson, AP Rapoport, ...
Cancer 110 (5), 1042-1049, 2007
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
A Badros, B Barlogie, E Siegel, M Cottler-Fox, M Zangari, A Fassas, ...
Journal of clinical oncology 20 (5), 1295-1303, 2002
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma
WG Tong, R Chen, W Plunkett, D Siegel, R Sinha, RD Harvey, AZ Badros, ...
Journal of clinical oncology 28 (18), 3015, 2010
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
J Shaughnessy Jr, E Tian, J Sawyer, K Bumm, R Landes, A Badros, ...
Blood, The Journal of the American Society of Hematology 96 (4), 1505-1511, 2000
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20